Stock Mover of the Day: Is Xencor Inc a Buy? The Stock Reaches All Time High Today

Stock Mover of the Day: Is Xencor Inc a Buy? The Stock Reaches All Time High Today

The stock of Xencor Inc (NASDAQ:XNCR) reached all time high today, Nov, 16 and still has $44.43 target or 64.00% above today’s $27.09 share price. This indicates more upside for the $1.16 billion company. This technical setup was reported by Barchart.com. If the $44.43 PT is reached, the company will be worth $742.40M more.
Trading stocks at an all time highs is usually a winning strategy. An all time high points to a stock which has the most positive fundamentals ever. Even thought the pullback rate is high, if correct risk management is utilized, investors can trade very well such events. About 58,842 shares traded hands. Xencor Inc (NASDAQ:XNCR) has risen 81.06% since April 14, 2016 and is uptrending. It has outperformed by 76.37% the S&P500.

Xencor Inc (NASDAQ:XNCR) Ratings Coverage

Out of 5 analysts covering Xencor (NASDAQ:XNCR), 4 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 80% are positive. Xencor has been the topic of 7 analyst reports since August 5, 2015 according to StockzIntelligence Inc. The firm earned “Outperform” rating on Thursday, September 17 by Leerink Swann. The rating was downgraded by Zacks to “Hold” on Saturday, August 8. The firm has “Hold” rating given on Friday, September 4 by Zacks. The rating was initiated by Canaccord Genuity on Tuesday, December 22 with “Buy”. The stock of Xencor Inc (NASDAQ:XNCR) earned “Outperform” rating by Leerink Swann on Tuesday, March 8. The firm has “Overweight” rating by Piper Jaffray given on Tuesday, October 4. The stock of Xencor Inc (NASDAQ:XNCR) earned “Buy” rating by MLV on Wednesday, August 5.

According to Zacks Investment Research, “Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.”

Insitutional Activity: The institutional sentiment increased to 1.64 in Q2 2016. Its up 0.40, from 1.24 in 2016Q1. The ratio is positive, as 10 funds sold all Xencor Inc shares owned while 23 reduced positions. 13 funds bought stakes while 41 increased positions. They now own 27.63 million shares or 4.30% less from 28.87 million shares in 2016Q1.
Dekabank Deutsche Girozentrale reported 23,700 shares or 0% of all its holdings. Qvt Fincl L P owns 386,925 shares or 0.51% of their US portfolio. Moreover, Mufg Americas has 0% invested in Xencor Inc (NASDAQ:XNCR) for 988 shares. Moreover, Ecor1 Capital Limited Com has 1.26% invested in Xencor Inc (NASDAQ:XNCR) for 168,000 shares. Creative Planning has 0.01% invested in the company for 37,475 shares. Vanguard Grp holds 1.34M shares or 0% of its portfolio. Moreover, Morgan Stanley has 0% invested in Xencor Inc (NASDAQ:XNCR) for 39,156 shares. Moreover, Credit Suisse Ag has 0% invested in Xencor Inc (NASDAQ:XNCR) for 27,385 shares. Geode Ltd Liability Com holds 0% or 236,224 shares in its portfolio. Equitec Specialists Ltd Llc holds 5,489 shares or 0.02% of its portfolio. Sphinx Trading Lp holds 4.84% of its portfolio in Xencor Inc (NASDAQ:XNCR) for 128,018 shares. Price T Rowe Associates Inc Md reported 575,316 shares or 0% of all its holdings. Voya Investment Mgmt Llc last reported 0% of its portfolio in the stock. Springbok Capital Ltd Liability Corporation has 5,400 shares for 0.01% of their US portfolio. Jpmorgan Chase last reported 288,950 shares in the company.

Insider Transactions: Since May 24, 2016, the stock had 0 insider buys, and 18 sales for $8.24 million net activity. Another trade for 1,250 shares valued at $18,875 was made by Baracchini Edgardo Jr on Tuesday, June 28. $523,059 worth of Xencor Inc (NASDAQ:XNCR) shares were sold by STAFFORD JOHN S III. On Tuesday, August 30 the insider Dahiyat Bassil I sold $872,028. Another trade for 1,183 shares valued at $20,123 was sold by Foster Paul A. 3,400 shares were sold by CARTER BRUCE L A, worth $77,074 on Thursday, August 11. $354,065 worth of Xencor Inc (NASDAQ:XNCR) was sold by Desjarlais John R on Tuesday, August 23.

More notable recent Xencor Inc (NASDAQ:XNCR) news were published by: Prnewswire.com which released: “Xencor Presents Preliminary Data from an Ongoing, Open-label, Phase 2 Study of …” on November 13, 2016, also Prnewswire.com with their article: “Xencor Presents Preclinical Data on XmAb20717 Dual Checkpoint Blockade and …” published on November 11, 2016, Fool.com published: “This Caused Xencor Inc.’s Stock to Jump 11.6% in August” on September 10, 2016. More interesting news about Xencor Inc (NASDAQ:XNCR) were released by: Fool.com and their article: “Why Xencor Inc’s Shares Are Skyrocketing Today” published on June 28, 2016 as well as Prnewswire.com‘s news article titled: “Xencor to Host Third Quarter 2016 Financial Results Webcast and Conference …” with publication date: October 26, 2016.

XNCR Company Profile

Xencor, Inc., incorporated on June 8, 2004, is a clinical-stage biopharmaceutical company. The Firm is focused on discovering and developing engineered monoclonal antibodies to treat severe and life threatening diseases. The Company’s segment is related to the development of pharmaceutical products. The Firm uses its XmAb technology platform to create antibody product candidates designed to treat autoimmune and allergic diseases, cancer and other conditions. The Company’s clinical stage product candidates include XmAb5871, which is being developed for autoimmune disease, and XmAb7195, which is being developed for asthma and allergic diseases. The Company’s oncology product candidates are in preclinical stage, which include XmAb14045 for the treatment of acute myeloid leukemia (AML) and XmAb13676 for B-cell malignancy. In addition to its compounds in clinical development, the Company uses its XmAb technology to create antibody compounds which are licensed to other pharmaceutical and biotechnology companies for further development, which include XmAb5574/MOR208 (MOR208), an antibody drug candidate, and XmAb13551, a bispecific CD38 x CD3 preclinical candidate.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment